Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
- 2025-04
-
CRF and urocortin produce marked
2019-09-06
CRF and urocortin 1 produce marked effects on the dapt secretase when administered both i.v. or directly into the CNS (Parkes et al., 2001). Systemic i.v administration of CRF and urocortin 1 cause a marked and long-lasting reduction in mean arterial blood pressure in rats Briscoe et al., 2000, Lawr
-
br Materials and methods br Results The i v
2019-09-06
Materials and methods Results The i.v. administration of urocortin 2 reduced the mean arterial blood pressure in a dose-dependent manner (Fig. 1). The ED50 for the urocortin 2 cumulative dose–response effect on mean arterial blood pressure was 0.014±0.004 mg kg−1. Urocortin 2 administration ha
-
Partial suppression of the cot
2019-09-06
Partial suppression of the cot-1 (ts) phenotype by deletion of gul-1 has been well documented (Seiler et al., 2006). This is now also very clearly evident in the transcriptional profile of the various strains (Fig. 2). Furthermore, the comparative analysis of the single and double mutants revealed,
-
Compared to ET all agonists
2019-09-05
Compared to ET-1, all agonists tested showed a 2–4 fold bias for the G protein constrictor assay compared to the β-arrestin assay (Table 1). This preliminary analysis indicated that at least modest pathway bias for endogenous ET peptides is possible, however the physiological significance of this, i
-
E ubiquitin ligases are key
2019-09-05
E3 ubiquitin ligases are key players in the ubiquitin-proteasome pathway because they catalyse ubiquitination of substrate proteins.39, 40, 41 As important regulators of cellular ubiquitination, E3 ligases are emerging as attractive drug targets, particularly in cancer.42, 43, 44 However, E3 ligases
-
stat3 The data correlations from Multiflash and DIPPR
2019-09-05
The data correlations from Multiflash™ [43] and DIPPR [44] were used for the liquid volume and heat of vaporization. For vapour pressure the curves were regressed from the experimental data present on both the DIPPR [44] and TRC [45] databases. As for liquid heat capacities both the latter databases
-
br Concluding Remarks Recent studies
2019-09-05
Concluding Remarks Recent studies have provided unprecedented details of APC/C structure and enzymology, which explain how the activity of this massive E3 ligase is controlled, and how ubiquitylation is achieved to temporally regulate cell division. Although one pervasive question has been why th
-
Another important new result that
2019-09-05
Another important new result that has expanded the range of functions of iPLA2-VIA in physiology and pathophysiology is its implication in macrophage polarization under stimulation conditions. Ashley et al. [129] described in peritoneal macrophages from Pla2g6−/− mice that the absence of iPLA2-VIA f
-
Enzyme selectivity of many enzymes like galactosidases acyla
2019-09-05
Enzyme selectivity of many MPC 6827 hydrochloride clinical like β-galactosidases, acylases, epoxyhydrolases, lipases, etc. has also been modulated by using different immobilization techniques. It can result in the selection of optimal biocatalyst for different processes. This has many advantages ov
-
The growth inhibitory effect of PGE
2019-09-04
The growth inhibitory effect of PGE2 has been linked to the ability of Gs coupled PGE2 receptors EP2 and EP4 to mediate elevation of cAMP [22], [23]. Evidence suggests that this mechanism may not be the key cause of growth inhibition [24]. In various cell types, EP4 receptor has been shown to utiliz
-
Finally we assessed the utility of monitoring
2019-09-04
Finally, we assessed the utility of monitoring cfDNA in terms of predicting disease progression earlier than radiological progression. These patients may have a chance to receive subsequent chemotherapy before worsening symptoms. Although the number of the patients who experienced progression was re
-
The current study provides evidence for
2019-09-04
The current study provides evidence for a previously unknown role for DHODH as a growth/survival factor in KRAS mutant tumors. While many aspects of the link between DHODH inhibition and survival of KRAS mutant cells remain to be established, de novo pyrimidine biosynthesis appears to be a crucial p
-
As part of a program
2019-09-04
As part of a program to explore the key binding interactions between the core of 1 and DGAT-1 a systematic analysis of the aminopyrimidine subunit was initiated. A potential approach to improving passive permeability within this series would be to increase lipophilicity via incorporation of substitu
-
The IV chains of mature GBM are built exclusively by
2019-09-04
The α3/α4/α5(IV)-chains of mature GBM are built exclusively by podocytes (not by endothelial cells) (Abrahamson et al., 2009), placing the podocytes into the focus of GBM-diseases such as Alport syndrome. Alport syndrome (AS) is caused by mutations in the COL4A3, 4 or 5 genes coding for the α3/α4/α5
-
protein kinase br Materials and methods br
2019-09-04
Materials and methods Acknowledgements SD was supported by a pre-doctoral research fellowship from the Flanders Agency for Innovation and Entrepreneurship (VLAIO-Flanders, Belgium). YB is supported by a postdoctoral fellowship from Research Foundation Flanders (FWO, Belgium). We thank Isabelle
15611 records 944/1041 page Previous Next First page 上5页 941942943944945 下5页 Last page